Subclinical ocular alterations in Graves' disease: The FUMO score, a new tool to predict Graves' orbitopathy progression
Authors' conclusion
Subclinical ocular alterations can predict the progression of GO in patients with GD. The FUMO score, particularly when combined with TRAb and FT3 levels, reliably identifies patients at risk of developing overt GO, supporting its use for early risk stratification.
Study context
- Population
- Consecutive patients with Graves' disease (GD) without Graves' orbitopathy (GO); controls with non-autoimmune hyperthyroidismGD without GO
- Participants
- 156 patients
- Exposure
- Medium-high risk vs low risk FUMO score
- Controln = 45
- Outcome
- Onset of overt GO (accuracy of FUMO score in predicting it)
- Follow-up
- 24 months
Methodological detailsconsecutive patients, 24-month follow-up
- Consecutive patients
- 24-month follow-up
Main finding
As reported in the abstract
Overt GO
Model AUC
0.84
P < .0001
PPV
73%
NPV
72%
Observational data: associations, not effects.
Further findings
GO activity and severity · 24 months
- GO more frequently active and moderate-to-severe in medium-high risk patients
Predictors of GO (multiple logistic regression)
- TRAb levels and FUMO were the strongest independent predictors of GO; higher FT3 and smoking also conferred increased risk
Original publication
Subclinical ocular alterations in Graves' disease: The FUMO score, a new tool to predict Graves' orbitopathy progression. J Clin Endocrinol Metab. Published 2 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →